tw-healthcare-regulations

Taiwan Healthcare Regulations

Framework

IRON LAW: NHI Shapes Everything in Taiwan Healthcare

Taiwan's National Health Insurance (全民健保) covers 99.9% of the
population. Any healthcare product or service strategy in Taiwan must
account for NHI — either by getting NHI reimbursement (volume play)
or by positioning as self-pay/premium (margin play).

Ignoring NHI is like ignoring gravity.

NHI System Overview

Aspect	Detail
Coverage	99.9% of population (23M+ people)
Single payer	衛生福利部中央健康保險署 (NHIA)
Premium	5.17% of insured salary (shared: employer 60%, employee 30%, government 10%)
Co-pay	Outpatient: NT$50-420. Hospitalization: 5-30% (capped)
Drug pricing	NHIA sets reimbursement prices via Drug Expenditure Target (DET)
Annual budget	~NT$800B+ (growing 4-5% annually)

Medical Device Regulatory Path

Class	Risk	Examples	Approval Path	Timeline
Class I	Low	Bandages, tongue depressors	Registration (listing)	1-2 months
Class II	Medium	Blood pressure monitors, surgical gloves	Technical review	6-12 months
Class III	High	Implants, AI diagnostic software	Full clinical review	12-24 months
SaMD (Software as Medical Device)	Varies by intended use	AI diagnosis, clinical decision support	Class II or III depending on risk	6-24 months

Regulatory body: 衛生福利部食品藥物管理署 (TFDA)

Digital Health Regulatory Landscape

Category	Regulation Status	Key Rule
Telemedicine	Expanded post-COVID (通訊診察治療辦法)	Allowed for follow-up visits, chronic disease, remote areas. Initial visits still require in-person for most cases.
AI diagnostics	SaMD regulation applies	If AI makes/assists clinical decisions, it's a medical device requiring TFDA approval
Health apps	Unregulated if wellness-only	Crosses into medical device territory if it diagnoses, treats, or monitors a medical condition
Health data	個人資料保護法 (PDPA) + 醫療法	Medical records have stricter protection than general personal data. Patient consent required for data use.
Electronic medical records	醫療機構電子病歷製作及管理辦法	EMR systems must meet MOHW standards. Cloud storage allowed with conditions.

Regulatory Decision Tree for Digital Health Products

Does your product diagnose, treat, or monitor a medical condition?
├── NO → Not a medical device. General consumer regulations apply.
└── YES → Medical device (SaMD)
    ├── Does it provide clinical decision support?
    │   ├── Autonomous (AI decides) → Class III
    │   └── Assistive (human decides) → Class II
    └── Does it monitor vital signs?
        ├── Clinical grade → Class II-III
        └── Wellness/fitness → Likely not regulated (but verify with TFDA)

Output Format

# Healthcare Regulatory Assessment: {Product}

## Product Classification
- Type: Medical device / Wellness / SaMD / Telemedicine
- Risk class: I / II / III
- Regulatory body: TFDA / NHIA / None

## Regulatory Pathway
| Step | Action | Timeline | Cost |
|------|--------|----------|------|
| 1 | {regulatory step} | {months} | NT${X} |

## NHI Strategy
- NHI reimbursement: Pursuing / Not pursuing
- If pursuing: {reimbursement category, pricing strategy}
- If not: {self-pay positioning, target market}

## Compliance Checklist
- [ ] TFDA classification confirmed
- [ ] Clinical data requirements identified
- [ ] Data privacy (PDPA + medical records) compliant
- [ ] NHI reimbursement strategy decided

Gotchas

• NHI price pressure is relentless: NHI reimburses at set prices that are revised downward periodically. Building a business dependent on NHI reimbursement means accepting margin erosion over time.
• SaMD regulation is evolving rapidly: TFDA is still developing frameworks for AI-based medical devices. What's unregulated today may require approval tomorrow. Monitor regulatory changes actively.
• Clinical trials may be required: Class III devices and some Class II devices need clinical evidence. Budget 12-24 months and NT$5-20M+ for clinical trials in Taiwan.
• Hospital procurement is relationship-driven: Taiwan's major hospitals (台大, 長庚, 榮總) have procurement committees, but relationships with key opinion leaders (KOLs) in medicine are critical for adoption.
• This is educational guidance, not regulatory advice: Taiwan healthcare regulations are complex and change frequently. Consult TFDA directly or engage a regulatory affairs consultant for specific product submissions.

References

• For TFDA submission procedures, see references/tfda-submission.md
• For NHI reimbursement application process, see references/nhi-reimbursement.md